

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 August 2018 (02.08.2018)



(10) International Publication Number
WO 2018/140299 A1

(51) International Patent Classification:
C07D 417/14 (2006.01) *A61P 25/28* (2006.01)
A61P 25/00 (2006.01) *A61K 31/445* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2018/014331

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
19 January 2018 (19.01.2018)

(25) Filing Language: English

Published:

- with international search report (Art. 21(3))

(26) Publication Language: English

(30) Priority Data:
62/451,137 27 January 2017 (27.01.2017) US

(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).


(72) Inventors: DREYFUS, Nicolas Jacques Francois; c/o
ELI LILLY AND COMPANY, P.O. Box 6288, Indianapo-
lis, Indiana 46206-6288 (US). LINDSAY-SCOTT, Peter
James; c/o ELI LILLY AND COMPANY, P.O. Box 6288,
Indianapolis, Indiana 46206-6288 (US).

(74) Agent: LENTZ, Nelsen L. et al.; ELI LILLY AND COM-
PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: N-[4-FLUORO-5-[[[(2S,4S)-2-METHYL-4-[(5-METHYL-1,2,4-OXADIAZOL-3-YL)METHOXY]-1-PIPERIDYL]METHYL]THIAZOL-2-YL]ACETAMIDE AS OGA INHIBITOR



Formula I

(57) Abstract: The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.

WO 2018/140299 A1